Related Experiment Video
Updated: May 26, 2026
08:50
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
Endogenous Engineering Reprograms Extracellular Vesicles for Enhanced Therapeutic Function
Jinghui Wang1,2, Wenxuan Zhao2, Xiaoming Hu2
1Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.
Summary
Researchers are reprogramming cells to engineer extracellular vesicles (EVs) for targeted drug delivery. This involves modifying cells genetically and environmentally to load proteins and nucleic acids for treating diseases like cancer and cardiovascular conditions.
Area of Science:
- Biotechnology
- Cell Biology
- Nanomedicine
Background:
- Extracellular vesicles (EVs) are natural carriers of therapeutic molecules.
- EV biogenesis pathways offer opportunities for cargo regulation.
- Engineering EVs enhances their therapeutic potential.
Purpose of the Study:
- To review strategies for reprogramming EV-producing cells to load functional proteins and nucleic acids.
- To explore the combination of environmental cues and genetic programming for EV engineering.
- To summarize therapeutic applications and future directions in EV-based therapeutics.
Main Methods:
- Modulating cellular environments to influence EV cargo.
- Genetic engineering of cells for protein and nucleic acid recruitment into EVs.
- Utilizing intrinsic EV sorting machinery and engineered molecular interactions.
- Leveraging RNA-binding proteins (RBPs) and sorting motifs for nucleic acid loading.
Main Results:
- Demonstrated strategies for loading proteins via physiological stimuli and genetic systems (scaffold fusion, peptide tags).
- Highlighted methods for enriching nucleic acids (miRNAs, mRNAs, RNP complexes) through environmental changes and targeted loading.
- Summarized successful therapeutic applications in cardiovascular, hepatic, neurological diseases, and cancer.
Conclusions:
- Cellular reprogramming offers a powerful approach for engineering EVs with specific therapeutic cargos.
- Combined environmental and genetic strategies enhance the efficiency and specificity of EV loading.
- Further advancements in discovery, biomanufacturing, and standardization are crucial for clinical translation of EV therapeutics.
